Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). In a filing disclosed on June 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on May 15th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.

Regeneron Pharmaceuticals Trading Down 2.4%

Shares of REGN traded down $14.53 during mid-day trading on Wednesday, reaching $601.65. 815,504 shares of the company’s stock traded hands, compared to its average volume of 1,195,825. The stock has a market cap of $63.61 billion, a P/E ratio of 14.66, a P/E/G ratio of 1.35 and a beta of 0.25. The stock’s 50-day moving average is $698.64 and its two-hundred day moving average is $740.06. Regeneron Pharmaceuticals, Inc. has a 12 month low of $503.25 and a 12 month high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s quarterly revenue was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $8.22 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a dividend of $0.94 per share. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sound Shore Management Inc CT bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $64,677,000. Ellerson Group Inc. ADV lifted its holdings in shares of Regeneron Pharmaceuticals by 49.2% during the 3rd quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company’s stock valued at $4,556,000 after purchasing an additional 2,671 shares during the last quarter. Nordea Investment Management AB lifted its holdings in shares of Regeneron Pharmaceuticals by 118.1% during the 4th quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after purchasing an additional 74,350 shares during the last quarter. Oppenheimer & Co. Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 7.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 23,714 shares of the biopharmaceutical company’s stock valued at $13,334,000 after purchasing an additional 1,597 shares during the last quarter. Finally, TD Asset Management Inc lifted its holdings in shares of Regeneron Pharmaceuticals by 15.9% during the 3rd quarter. TD Asset Management Inc now owns 374,264 shares of the biopharmaceutical company’s stock valued at $210,437,000 after purchasing an additional 51,407 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron-backed Parabilis Medicines completed a record-setting biotech IPO, pricing above the expected range and raising about $670 million, plus roughly $75 million from a concurrent private placement to Regeneron. The successful debut suggests strong demand for the asset Regeneron helped finance, which can be viewed as a validation of Regeneron’s deal-making and capital allocation. Article Title
• Positive Sentiment: Regeneron also highlighted progress in its pipeline, with a new clinical study testing weekly Praluent dosing in cholesterol treatment. Any meaningful improvement in dosing convenience or efficacy could support longer-term product growth if the study produces favorable results. Article Title
• Neutral Sentiment: Parabilis’ IPO demand was reported to be exceptionally strong, with pricing above the initial range and shares surging on debut. This is mostly an external event, but it reflects favorably on Regeneron’s strategic backing of the company. Article Title
• Neutral Sentiment: Separately, Regeneron has been mentioned in recent articles about WHO support for an antibody therapy in Ebola-related research. While scientifically encouraging, the near-term market impact appears limited unless it translates into trial progress or commercialization. Article Title
• Negative Sentiment: Law-firm investigation headlines tied to Regeneron are likely pressuring the stock, as fraud/investigation notices can raise concerns about litigation risk and distract from the company’s fundamentals. Similar alerts from Pomerantz and Schall are adding to that overhang. Article Title

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on REGN shares. Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $800.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a report on Monday, May 18th. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Finally, Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $792.65.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.